SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD.
Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical Center Los Angeles, and also has a specialty practice in breast cancer.

Final results from the Phase 1 study, “A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors” are being prepared for submission to the FDA.

Presented by Monica Mita, MD

Download the Presentation here.